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ABstRACt
Background & objectives: In Venezuela, Chagas disease (ChD) is considered a serious health problem, with about 
6 million people at risk; and acute outbreaks due to oral transmission of Chagas Disease (OChD) are becoming 
increasingly important. In 2007 there was a major outbreak of OChD and although patients from this episode were 
treated with nifurtimox (Lampit®—Bayer), about 70% therapeutic failure was registered. these results led us to 
examine whether parasite’s drug susceptibility was related to this therapeutic failure. 
Methods: the Trypanosoma cruzi parasites were isolated by haemoculture of the peripheral blood drawn from the 
pre- and post-nifurtimox treated patients infected in the 2007 OChD outbreak at Caracas, Venezuela. the in vitro 
assays for drug testing were performed by the Mtt methodology followed by calculation of inhibitory concentra-
tion-50 (IC50) values. 
Results: Parasite isolates obtained from the infected patients prior and after nifurtimox treatment when subjected 
to variable concentrations of the drug showed great heterogeneity in susceptibility with IC50 values ranging from 
4.07 ± 1.82 to 94.92 ± 7.24 µM. 
Interpretation & conclusion: the high heterogeneity in nifurtimox IC50 values in the isolates and clones from the 
OChD patients, suggests that the therapeutic failure to nifurtimox could be due in part to a phenotypic variability 
that existed in the wild parasite population at the original source of contamination. though, further pharmacological 
studies are needed to confirm the existence of natural nifurtimox resistance in the parasite.
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INtRODUCtION
the protozoan Trypanosoma cruzi is the etiological 
agent of Chagas disease (ChD), which ranks among the 
world’s most neglected diseases. According to the esti-
mates of the Pan American Health Organization and the 
World Health Organization (WHO) there are 6 to 7 million 
people infected with T. cruzi worldwide with the great 
majority being in Latin America1–2.
In Venezuela, nearly 6 million people living in 198 
municipalities and 14 federal entities are considered to 
be at risk3. In humans, although the main route of T. cruzi 
infection is through the contamination of skin wounds 
with triatomines faeces containing metacyclic trypomas-
tigotes; other modes of transmission, such as blood trans-
fusion, organ transplantation, congenital, laboratory acci-
dents and oral transmission have also been documented4–5. 
Given a large number of reports of acute outbreaks of oral 
Chagas disease (OChD) in the last decade, the importance 
of the type of transmission is increasing6–9.
Since 2007 when we reported the world’s first largest 
oral transmission, 14 outbreaks of OChD have been docu-
mented in Venezuela8, 10–11. In the 2007 outbreak, medical and 
parasitological monitoring of nifurtimox treated-patients 
was not entirely satisfactory, and after eight years of treat-
ment, about 70% of the patients showed persistent IgG, 
lytic antibodies, positives PCRs for kinetoplast DNA 
markers, and in some cases circulating parasites in the 
peripheral blood11. the reasons for treatment failures are 
unknown, but among the potential causes are variable drug 
susceptibility in T. cruzi populations, characteristics of the 
host’s immune system and/or unfavourable drug pharma-
cokinetics properties12. since differences in drug suscep-
tibility have been experimentally determined in T. cru-
zi isolates from different geographic areas13–20, we believe 
that T. cruzi populations naturally resistant to benznidazole 
and nifurtimox can be considered as an important factor 
behind the low cure rates observed in that outbreak15–17. 
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This study for the first time describes the experimental 
susceptibility/resistance of T. cruzi parasites to nifurtimox 
in pre- and post-treated patients infected with OChD dur-
ing the 2007 outbreak using trypomastigotes–the flagel-
ated stage of trypanosomes found in peripheral blood.
MAtERIAL & MEtHODs
Patient and parasite isolates
this study was conducted in 2018 (January to 
November) involving OChD patients of the 2007 Chacao 
(city in Caracus) outbreak, diagnosed and treated at the 
section of Immunology, Institute of tropical Medicine in 
Caracas, Venezuela. Patients were administered nifurti-
mox orally at doses of 8 mg/kg/day, divided into two doses 
for 90 continuous days. the clinical follow-up ensured the 
compliance of the treatment in all the patients.
seven pre-treatment (Pre-tt) and four post-nifurti-
mox treatment samples isolated from peripheral blood 
from different patients were used. the isolates of T. cruzi 
were obtained by haemoculture (Hm) following the meth-
od proposed by Filardi and Brener16 and preserved in liver 
infusion-tryptose (LIt) medium supplemented with 10% 
fetal bovine serum (FBs) and 10% dimethyl sulfoxide 
(DMsO) at –194 °C. two international reference isolates 
were used as controls: Dm28c, naturally resistant to ni-
furtimox21 and Cl-Brener, naturally susceptible to nifurti-
mox22. their characteristics are shown in table 1.
In vitro host cell line
For in vitro cell infections we used African green 
monkey kidney epithelial cells (Vero cell-AtCC), kindly 
donated by the Instituto Nacional de Higiene “Rafael 
Rangel” (INHRR, Caracas-Venezuela). Cells were cul-
tured in minimal essential medium (MEM) supplemented 
with 5% FBs and incubated at 37 °C in an atmosphere of 
5% CO2.
Cellular infection
trypomastigote stages derived from each isolate were 
differentiated from aged epimastigotes culture in a 10:1 
ratio (aged epimastigote: Vero cells). When trypomasti-
gotes started to emerge from Vero cells, the concentra-
tion of living parasites was determined using a Neubauer 
chamber.
Parasite cloning
Clones from the isolates listed in table 1 were ob-
tained from the trypomastigotes released from Vero cells 
using the methodology described by Goldberg and Chi-
ari26 with some modifications. A single trypomastigote, 
isolated by serial dilution, and assessed by light micros-
copy, was placed in each of the 96-well plates containing 
approximately 500 Vero-AtCC cells per well. the plate 
was incubated at 37 °C in a 5% CO2 atmosphere and fol-
lowed up for 15–20 days until the parasite´s growth was 
observed. Free trypomastigotes were then transferred to 
cell culture flasks with 70% confluent Vero-ATCC cells, 
and further cultured in blood agar + LIt medium supple-
mented with 10% inactivated FBs and 1% of the penicil-
lin-streptomycin solution. two clones were generated for 
each parasite isolate. 
Reagents
Nifurtimox is a commercial drug from Bayer Lab-
oratories (Germany). the 100 mg of this drug was dis-
solved in DMSO, keeping DMSO final concentration not 
exceeding 1% v/v. Before each test, drug dilutions were 
prepared in MEM.
In vitro assays for drug testing
About 100 μl of trypomastigotes were added at a con-
centration of 1×108 parasites/ml to each of the 96-wells of 
a flat bottom plate. Immediately 50 μl of nifurtimox was 
added at various concentrations (0.0348, 0.348, 3.480, 
34.80, 348 µM). Plates were incubated at 37 °C for 24 h. 
After the incubation, 20 μl of tetrazolium salt (MTT) was 
added to each well. Plates were incubated for 3 h at 37 
°C, and the formazan crystals were dissolved with a solu-
tion of 0.01% sDs in 0.1N HCl. the formazan crystals 
were quantified with a TECAN-Sunrise microplate reader 
at 570 nm. Each assay was done in triplicate with their 
respective controls without the drug24.
table 1. General characteristics of Trypanosoma cruzi isolates from 





status DtU Date of isolation
1593* Human Pre-treatment I December 2007
1595** Human Pre-treatment I December 2007
1601** Human Pre-treatment I December 2007
843.1*** Human Post-treatment I April 2008
843.2*** Human Post-treatment I May 2008
909*** Human Post-treatment I June 2008










VI        –
DtU– Discrete typing units; (*) – Reference no. 23; (**) – Reference 
no. 24; and (***) – Reference no. 24.
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Statistical analysis
Drug activity was expressed as the concentration 
necessary to inhibit parasitic growth by 50% (IC50)
24–27. A 
95% confidence interval was calculated using nonlinear 
regression with GraphPad Prism (Intuitive software for 
science, san Diego, CA, UsA) software. the results are 
shown as the mean ± standard deviation (sD) of three in-
dependent experiments.
Ethical statement
In order to obtain isolates of T. cruzi from peripheral 
blood of adults and children, patients signed an informed 
consent form, approved by the Ethics Committee of the 
Institute of tropical Medicine, Faculty of Medicine, Uni-
versidad Central de Venezuela (CEC-IMt 019/2010; De-
cember 10, 2010) .
REsULts
In vitro nifurtimox cytotoxicity on parental populations of 
Trypanosoma cruzi: Pre- and post-treatment 
As shown in table 2, nifurtimox susceptibility of 
OChD T. cruzi isolates from the 2007 Chacao outbreak 
was very heterogeneous with IC50 values ranging from 
4.07 ± 1.82 µM and 94.92 ± 7.24 µM. Figure 1 shows 
the survival curves of the isolates listed in table 1 after 
24 h exposure to different concentrations of nifurtimox. 
table 2. Nifurtimox inhibitory concentration50 (IC50) values obtained 
from Trypanosoma cruzi from patients with oral Chagas disease of 

































1593-C2     0.03 ± 0.009
1595  64.40 ± 8.42 1595-C1           ND NA
1595-C2           ND
1601  22.35 ± 2.87 1601-C1   98.31 ± 4.57 NA








843.1    4.07 ± 1.82 843.1-C1 210.76 ± 10.26 NA
843.1-C2     2.92 ± 1.28
843.2  43.31 ± 4.14 843.2-C1   43.29 ± 5.94 NA
843.2-C2 284.32 ± 6.83
909  30.39 ± 3.31 909-C1 736.59 ± 15.04 NA
909-C2 721.19 ± 8.79






   4.51 ± 0.34 NA NA #
Dm28c  19.19 ± 1.54 NA NA 10.0 ± 0.4
Ref.: International reference strain28; ND: Not determined; NA: Not applicable; 
#No reference values found.
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Fig. 1: survival curves for Trypanosoma cruzi trypomastigotes treat-
ed with nifurtimox after 24 h incubation: (a) Pre-treatment 
isolates; (b) Post-treatment isolates; and (c) strains of interna-
tional reference Dm28c (naturally resistant to nifurtimox) and 
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Fig. 2: Dose-response of clones derived from the original parental 
isolates. Pre-treatment: (a) 1593; (b) 1595; (c) 1601; Post-








In the case of the Pre-Tt isolates (Fig. 1a) at 100 μg/ml 
(348 μM), a 100% cytotoxic effect was achieved in all 
isolates. However, IC50 values revealed heterogeneity in 
the results, showing up to three times more susceptibility 
in isolates 1601 and 1593 (22.35 and 23.31 μM, respec-
tively) than isolate 1595 (64.40 μM).
the estimated average survival for the Pre-tt isolates 
at a nifurtimox concentration of 4.5 μM, which is the plas-
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ma concentration after an extravascular administration of 
the drug, was approximately 85%, i.e. a maximum effi-
ciency close to 15%. 
Regarding nifurtimox cytotoxicity in Post-tt isolates 
(Fig. 1b), sample 875 did not reach a 100% cytotoxic ef-
fect at the largest nifurtimox dose (348 µM). Pre-tt sam-
ples did not show a cytotoxic effect greater than 50% at 
the plasma concentrations of nifurtimox (4.5 μM). These 
corroborate the presumed resistant phenotype observed in 
the pre-tt populations.
Isolate 843.1, was the only one not following this 
trend, showing survival of around 50% with an IC50 of 
4.07 ± 1.82 µM. these values can be considered as ni-
furtimox susceptible when compared with the resistant 
reference strain Dm28c (Fig. 1c).
In order to check isolates phenotype stability, the ni-
furtimox assays were done a week apart in triplicate. Ad-
ditionally, nifurtimox sub-cultures susceptibility after a 
follow up of eight months showed no significant variation 
(results not shown).  
An interesting finding emerged when in vitro assays 
were performed to evaluate the nifurtimox resistance in 
two independent samples isolated from the same patient 
a month apart after receiving nifurtimox treatment at 8 
mg/kg for 90 days. these two Post-tt isolates designated 
843.1 and 843.2 showed different susceptibility to the ni-
furtimox (Fig. 1b) with IC50 values of 4.07 ± 1.82 μM 
and 43.31 ± 4.14 μM, respectively, i.e. the 843.1 isolate 
presented a 10-fold reduction in nifurtimox susceptibility. 
Figure 1b also reveals that at the plasma concentration of 
nifurtimox (4.5 μM), 843.2 isolate showed approximately 
a 2-fold higher survival than isolate 843.1. 
In vitro nifurtimox cytotoxic effect in cell clones derived 
from parent T. cruzi isolates from the pre and post-treat-
ment patients with oral Chagas disease
Figure 2 showing the survival curves for different 
clones from the same parental stock display high hetero-
geneity in IC50 values. the IC50 overall variation among 
clones ranged from 0.03 ± 0.009 μM (clone 2 from isolate 
1593) to 736.59 ± 15.04 μM (clone 1 from isolate 909). 
the greatest variability to nifurtimox was observed in 
clones from isolates 1593 (Fig. 2a), 909 (Fig. 2f) and 875 
(Fig. 2g), where IC50 differences among clones from the 
same isolate varied up to 80 fold in nifurtimox suscep-
tibility. In the case of clone 2 from isolate 875, a 100% 
decrease in sensitivity was observed at the plasma con-
centration of the drug, whereas in clone number 2 from 
isolates 1593 (Fig. 2b) and 843.1 (Fig. 2d) the sensitivities 
to the drug were higher with IC50 values of 0.03 and 2.92 
μM, respectively. These IC50 values  are up to 150 times 
smaller than the values  obtained for the CL-Brener strain 
(control strain for susceptibility).
DIsCUssION
the natural resistance of T. cruzi populations to nitro-
derivatives is described as an important factor that could 
explain therapeutic failure in humans and experimental 
models. Although these compounds have been used for 
decades in the treatment of Chagas disease, the biological 
behavior of their components on the parasitic stages of T. 
cruzi remains poorly understood. Here we present one of 
our few works in which T. cruzi trypomastigotes forms 
have been used as experimental models. these trypomas-
tigotes were obtained from patients affected by OChD pre- 
or post-treatment with nifurtimox. In general, the parasite 
populations isolated from these patients showed a natural 
resistance to nifurtimox. the IC50 values for some isolates 
were similar or larger than the resistant strain Dm28c. this 
result is similar to the IC50 values of 10.00 ± 0.4 μM and 
17.4 ± 5.1 μM reported by Vázquez-Rodríguez et al28 for 
trypomastigotes and epimastigote forms, respectively.
In the case of Pre-tt isolates 1601 and 1595, we found 
a 5- to 14.3-fold increase in the IC50 values when com-
pared with the reference strain Dm28c, thus revealing that 
the parental nifurtimox resistant phenotype was present 
in the original inoculum. some authors have reported that 
within T. cruzi DtUI isolates from the wildlife cycle have 
a natural resistance to nifurtimox29.
Comparing the Pre-tt isolates with the Post-tt clones 
we registered up to 80-fold variability in IC50 values to ni-
furtimox. therefore, it could be inferred that the increase 
in drug concentrations in the Post-tt isolates have affect-
ed, in a certain way, the phenotypic, physiological or ge-
netic characteristics of the original parasitic populations, 
but so far we do not have the experimental confirmation 
for this claim.
However, in the long-term, we can’t exclude that the 
nifurtimox treatment may select for even more resistant 
phenotypes, as has been reported by Veloso et al30 who 
induced benznidazole resistance to isolates obtained from 
dogs that have not received treatment for a long time. 
these resistant parasites were able to retain the resistant 
phenotype up to six months in the absence of the drug31. 
this result with Benznidazole could be extrapolated to 
ours if we take into consideration that Wilkinson et al32 
have detected cross-resistance to both the drugs.
As an exception for this tendency Post-tt isolate 
843.1, displayed increased susceptibility to nifurtimox. 
Although this behavior is difficult to explain, we believe 
that this particular isolate was present in the original in-
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oculum and managed to avoid the host immune system by 
having higher virulence and/or a particular histotropism 
for tissues where an effective concentration of the drug was 
not possible to be achieved. Along these lines Martins33 
found that when mice were inoculated with a mixture 
of Benznidazole susceptible and resistant isolates, they 
were able to recover one more susceptible isolate after 
Benznidazole treatment. However, the authors did not 
provide an explanation for this apparent lack of selec-
tion process. the prior knowledge of IC50 values of the 
three Pre-Tt patients (22.35 ± 2.87 to 99.31 ± 4.57μM) 
may have helped us to suspect a nifurtimox therapeutic 
failure in these patients34–35. However, in opposition to 
this idea, Moreno et al36 reported their failure to predict 
benznidazole treatment efficacy through the use of IC50 
values.
CONCLUsION
Given the great heterogeneity in nifurtimox IC50 val-
ues in the isolates and clones from the OChD patients, we 
can infer that the therapeutic failure to nifurtimox could 
be due in part to a phenotypic variability that existed 
in the wild parasite population of the original source of 
contamination, which may or may not have a genetic basis. 
Although this aspect requires more experimental evidence, 
in future, the study of the pharmacological behavior of T. 
cruzi infective isolates may allow a differential and more 
suitable treatment regimen for OChD patients.
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